Immunotherapy, represented by immune checkpoint inhibitors (ICIs), has significantly improved the clinical efficacy of treating malignant tumors. Antitumor responses mediated by immune checkpoint inhibitors depend on the infiltration of T cells capable of recognizing and killing tumor cells.
Recent advances in stem cell technology are opening new horizons for patients suffering from incurable diseases and disorders. Stem cell-based therapies, including human pluripotent stem cells (hPSCs) and mesenchymal stem cells (MSCs), have recently emerged as a key player in regenerative medicine.
A medical journal published by the I.D. Institute for Stem Cell and Genome Research
A medical journal published by the I.D. Institute for Stem Cell and Genome Research
I.D. Educational Community
Join the I.D. Community, an interactive environment bringing together experts, alumni, and students. This community aims to:
Exchange Clinical Expertise: Discuss challenging medical cases to enhance treatment outcomes.
Discuss Cutting-edge Research: Explore contemporary debates such as Digital Twins, Gerontology, and AI in medicine.
Build Professional Networks: Connect with leaders in regenerative medicine and global health organizations.
I.D. Educational Community
Join the I.D. Community, an interactive environment bringing together experts, alumni, and students. This community aims to:
Exchange Clinical Expertise: Discuss challenging medical cases to enhance treatment outcomes.
Discuss Cutting-edge Research: Explore contemporary debates such as Digital Twins, Gerontology, and AI in medicine.
Build Professional Networks: Connect with leaders in regenerative medicine and global health organizations.
